96829-58-2
96829-58-2
Chemical Structure
Orlistat
Synonym(s): Tetrahydrolipstatin; Ro-18-0647
- No. CAS: 96829-58-2
- Formula:C29H53NO5
- Molecular Weight:495.73
IUPAC Name: (S)-1-((2S,3S)-3-hexyl-4-oxooxetan-2-yl)tridecan-2-yl formyl-L-leucinate
InChIKey: AHLBNYSZXLDEJQ-FWEHEUNISA-N
SMILES: O=C1[C@@H](CCCCCC)[C@H](C[C@@H](OC([C@@H](N([H])C([H])=O)CC(C)C)=O)CCCCCCCCCCC)O1
Biological Activity: Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity[1]. Anti-atherosclerotic effect[2].
| Referencia número | Nombre del producto | Pureza | Descripciòn | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Orlistat | 99.94% | Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity. Anti-atherosclerotic effect. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Orlistat (Standard) | 98.21% | Orlistat (Standard) is the analytical standard of Orlistat. This product is intended for research and analytical applications. Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity. Anti-atherosclerotic effect. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Orlistat-d3 | Orlistat-d3 is a deuterated labeled Orlistat. Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity.?Anti-atherosclerotic?effect. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Giorgia Cioccoloni, et al. Influence of fatty acid synthase inhibitor orlistat on the DNA repair enzyme O6-methylguanine-DNA methyltransferase in human normal or malignant cells in vitro. Int J Oncol. 2015 Aug;47(2):764-72. [Content Brief]
- [2]. Zaidatul Akmal Othman, et al. Anti-Atherogenic Effects of Orlistat on Obesity-Induced Vascular Oxidative Stress Rat Model. Antioxidants (Basel). 2021 Feb 6;10(2):251. [Content Brief]
